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BACKGROUND
Alcoholic hepatitis is a clinical syndrome characterized by jaundice and liver im-
pairment that occurs in patients with a history of heavy and prolonged alcohol use. 
The short-term mortality among patients with severe disease exceeds 30%. Predniso-
lone and pentoxifylline are both recommended for the treatment of severe alcoholic 
hepatitis, but uncertainty about their benefit persists.
METHODS
We conducted a multicenter, double-blind, randomized trial with a 2-by-2 factorial 
design to evaluate the effect of treatment with prednisolone or pentoxifylline. The 
primary end point was mortality at 28 days. Secondary end points included death 
or liver transplantation at 90 days and at 1 year. Patients with a clinical diagnosis of 
alcoholic hepatitis and severe disease were randomly assigned to one of four groups: 
a group that received a pentoxifylline-matched placebo and a prednisolone-matched 
placebo, a group that received prednisolone and a pentoxifylline-matched placebo, 
a group that received pentoxifylline and a prednisolone-matched placebo, or a group 
that received both prednisolone and pentoxifylline.
RESULTS
A total of 1103 patients underwent randomization, and data from 1053 were available 
for the primary end-point analysis. Mortality at 28 days was 17% (45 of 269 patients) 
in the placebo–placebo group, 14% (38 of 266 patients) in the prednisolone–placebo 
group, 19% (50 of 258 patients) in the pentoxifylline–placebo group, and 13% (35 of 
260 patients) in the prednisolone–pentoxifylline group. The odds ratio for 28-day 
mortality with pentoxifylline was 1.07 (95% confidence interval [CI], 0.77 to 1.49; 
P = 0.69), and that with prednisolone was 0.72 (95% CI, 0.52 to 1.01; P = 0.06). At 
90 days and at 1 year, there were no significant between-group differences. Serious 
infections occurred in 13% of the patients treated with prednisolone versus 7% of 
those who did not receive prednisolone (P = 0.002).
CONCLUSIONS
Pentoxifylline did not improve survival in patients with alcoholic hepatitis. Prednisolone 
was associated with a reduction in 28-day mortality that did not reach significance and 
with no improvement in outcomes at 90 days or 1 year. (Funded by the National Institute 
for Health Research Health Technology Assessment program; STOPAH EudraCT 
number, 2009-013897-42, and Current Controlled Trials number, ISRCTN88782125.)
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Alcoholic hepatitis is a distinct manifestation of alcoholic liver disease that is characterized by jaundice and liver 
failure. This condition develops in persons with 
a history of prolonged and heavy alcohol use.1 
The severity of alcoholic hepatitis is convention-
ally defined by Maddrey’s discriminant function, 
which is calculated as 4.6 × (patient’s prothrombin 
time in seconds − control’s prothrombin time in 
seconds) + patient’s serum bilirubin level in milli-
grams per deciliter; a value of 32 or higher indi-
cates severe alcoholic hepatitis that carries an 
adverse prognosis, with mortality of 20 to 30% 
within 1 month after presentation and 30 to 
40% within 6 months after presentation.2
A number of therapies have been evaluated for 
the treatment of alcoholic hepatitis, but only two 
drugs have been incorporated into the treatment 
guidelines published by the American Association 
for the Study of Liver Disease and the European 
Association for the Study of the Liver 3,4. In a 2008 
Cochrane meta-analysis of 15 randomized trials 
published since 1971 that compared glucocorti-
coids with placebo or no intervention, Rambaldi 
et al. investigated the role of glucocorticoid ther-
apy for this condition.5 Despite this apparent wealth 
of evidence, controversy persists. Advocates of the 
treatment cite significant reduction in short-term 
mortality, whereas detractors raise questions about 
the risks of sepsis and gastrointestinal hemor-
rhage with glucocorticoid therapy. In the largest 
placebo-controlled study to date, investigators 
treated 90 patients with prednisolone and found 
no benefit of that therapy over placebo adminis-
tered in a similar group of patients.6 This study 
was hampered by the inclusion of patients with 
moderate or severe alcoholic hepatitis and those 
with alcohol-related cirrhosis. In the only study 
we found that required histologic confirmation 
of alcoholic hepatitis in all patients, prednisolone 
was associated with a short-term reduction in 
mortality, but this benefit was not apparent after 
2 years.7,8 The systematic review by the Cochrane 
group revealed a trend toward a benefit with glu-
cocorticoids that was not statistically significant.5 
However a reanalysis of the five largest studies in-
dicated a significant benefit from glucocorticoids; 
in this meta-analysis, 28-day mortality among 
patients with discriminant function scores of 32 or 
higher was 20% among those who were treated 
with prednisolone, as compared with 34% among 
those who received placebo (P<0.001).9
Among four randomized, controlled trials in 
which pentoxifylline was compared with placebo 
for the treatment of alcoholic hepatitis, one showed 
a significant benefit.10 All 100 patients enrolled 
had a discriminant function that was greater than 
32. The mortality was 24.6% in the pentoxifylline 
group as compared with 46.1% in the placebo 
group (P = 0.04). The principal benefit related to 
pentoxifylline appeared to be a reduction in the 
number of deaths attributed to the hepatorenal 
syndrome. However, two meta-analyses have not 
shown any convincing benefit associated with 
pentoxifylline.11,12
Two small studies have compared glucocorti-
coids with pentoxifylline, but the results were in-
consistent.13,14 Two other studies have compared 
the effect of glucocorticoid monotherapy with 
that of combined treatment with glucocorticoids 
and pentoxifylline but showed no benefit from 
the addition of pentoxifylline.15,16 The purpose of 
our trial — Steroids or Pentoxifylline for Alco-
holic Hepatitis (STOPAH) — was to determine 
whether prednisolone or pentoxifylline adminis-
tered for a 28-day period reduced short-term and 
medium-term mortality among patients admitted 
to a hospital with severe alcoholic hepatitis.
Me thods
Study Design and Oversight
The design and rationale for the trial have been 
described previously.17 STOPAH was a multicenter, 
randomized, double-blind trial with a 2-by-2 fac-
torial design that was intended to evaluate the 
treatment effect of prednisolone and of pentoxi-
fylline in the management of severe alcoholic 
hepatitis. A trial-management group designed the 
study (see the protocol, available with the full 
text of this article at NEJM.org). The study was 
approved by the Multicenter Research Ethics Com-
mittee (reference number 09/MRE09/59), and clini-
cal trial authorization was received from the 
Medicines and Healthcare Products Regulatory 
Agency. Written informed consent was obtained 
from each patient or from his or her legal repre-
sentative until such time as the patient recovered 
mental capacity. The trial was conducted and re-
ported with fidelity to the protocol, the Medicines 
for Human Use (Clinical Trials) Regulations 2004, 
as amended in 2006, the European Union Clinical 
Trials Directive (Directive 2001/20/EC) guidelines, 
the principles of the International Conference on 
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Harmonisation Good Clinical Practice under the 
oversight of University Hospital Southampton NHS 
Foundation Trust, and the provisions of the Dec-
laration of Helsinki. An independent data moni-
toring and ethics committee, whose members were 
aware of the group assignments, was convened 
to review the conduct of the trial and to analyze 
primary end-point data, using prespecified stop-
ping guidelines, after the recruitment of 200, 400, 
and 800 patients, to avoid continued recruitment 
in the event that a definitive result had been 
achieved.
Data collected by site investigative teams were 
submitted to the clinical trials unit and analyzed 
by study statisticians. The first author wrote the 
first draft of the manuscript, with substantial 
contributions from the coauthors. All the authors 
vouch for the accuracy and completeness of the 
data and analyses.
Patients
The trial included patients with a clinical diagno-
sis of alcoholic hepatitis. Clinical diagnosis was 
chosen because the use of liver biopsy in this group 
of patients is uncommon, and the aim was to re-
cruit a large number of participants whose con-
dition would reflect as closely as possible the 
condition of patients seen in clinical practice.18,19 
Patients were recruited from January 2011 through 
February 2014 at 65 hospitals across the United 
Kingdom. All patients admitted with suspected 
severe alcoholic hepatitis were evaluated for eli-
gibility. A clinical diagnosis that was based on a 
history of recent excess alcohol consumption and 
the absence of other causes of liver disease was 
used for trial recruitment. Inclusion criteria were 
an age of 18 years or older, a clinical diagnosis of 
alcoholic hepatitis, an average alcohol consump-
tion of more than 80 g per day for men and more 
than 60 g per day for women, a serum bilirubin 
level greater than 80 μmol per liter (4.7 mg per 
deciliter), and a discriminant function of 32 or 
higher. Key exclusion criteria were jaundice for 
more than 3 months, cessation of alcohol con-
sumption for more than 2 months before ran-
domization, the presence of other causes of liver 
disease, a serum aspartate aminotransferase level 
greater than 500 IU per liter or serum alanine 
transaminase level greater than 300 IU per liter, 
and previous entry into the study within the pre-
ceding 6 months.
Standard supportive care and nutritional sup-
port were given to each patient. The clinician re-
sponsible for each patient made the decision re-
garding other treatments, such as terlipressin for 
patients in whom hepatorenal failure was devel-
oping, acid suppression for prophylaxis against 
gastrointestinal hemorrhage, antibiotics, and vita-
min supplementation. Patients with renal failure 
(defined as a creatinine level >500 μmol per liter 
[>5.7 mg per deciliter] or the requirement for re-
nal-replacement therapy), active gastrointestinal 
bleeding, or untreated sepsis, and patients requir-
ing inotropic support with epinephrine or nor-
epinephrine, were excluded unless the condition 
stabilized within the first 7 days after admission 
to the hospital.
Randomization
A Web-based computer system (Tenalea, Forms-
Vision) was used to enroll eligible patients and 
randomly assign them to study groups. The ran-
domization schedule was created with the use of 
Stata software, version 11 (StataCorp). Random-
ization was performed with a block size of four, 
with stratification according to geographic area 
and risk category. The high-risk category con-
sisted of patients who had had an occurrence of 
gastrointestinal bleeding, renal impairment, or 
sepsis before randomization. All other patients 
were assigned to the intermediate-risk category.
Patients were randomly assigned to one of four 
groups, with one group receiving a pentoxifylline-
matched placebo and a prednisolone-matched pla-
cebo, the second group receiving 40 mg of 
prednisolone daily and a pentoxifylline-matched 
placebo, the third group receiving 400 mg of pent-
oxifylline three times daily and prednisolone-
matched placebo, and the fourth group receiving 
40 mg of prednisolone daily and 400 mg of pent-
oxifylline three times daily. All patients were pre-
scribed treatment for 28 days.
End Points
The primary end point of the trial was mortality 
at 28 days. Secondary end points included mortal-
ity or liver transplantation at 90 days and at 1 year.
Statistical Analysis
We estimated that a sample of 513 patients re-
ceiving each active agent and an equal number 
not receiving each agent would be required to 
detect a reduction in 28-day mortality from 30% 
in the latter groups to 21% in the former groups. 
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Thus, in total, our trial would require enrollment 
of 1026 patients. We allowed for a rate of with-
drawal or loss to follow-up of approximately 10% 
and therefore aimed to recruit 1200 patients to 
the study.
The analysis was conducted on an intention-
to-treat basis. The comparison of mortality at 28 
days between treated and untreated groups was 
performed with the use of logistic regression, 
with adjustments for risk category (high or inter-
mediate) and factorial design. Mortality and rates 
of liver transplantation at 90 days and 1 year were 
compared with the use of the same strategy. A 
test for treatment interaction was performed as 
a secondary analysis. Cox proportional-hazards 
regression was used to compare 1-year survival 
among the groups, and Kaplan–Meier curves for 
1-year survival were plotted. All P values were 
two-sided.
A univariate logistic-regression analysis was 
performed for the end points of 28-day mortality, 
90-day mortality, and 1-year mortality. Separate 
models were fitted for conventional prognostic 
scores (discriminant function, Model for End-Stage 
Liver Disease score, Glasgow alcoholic hepatitis 
score, and Lille score) and for clinical and labo-
ratory variables, to investigate whether they were 
significant predictors of mortality. As part of a 
prespecified analysis, individual and treatment 
variables that were found to be significant in uni-
variate analyses were used in multivariate logistic-
regression analysis, and backward elimination 
(which was not prespecified) was applied at a 5% 
significance level.
R esult s
Patients
Over a 3-year period, 5234 patients were screened, 
and after the application of eligibility criteria, 1103 
patients were randomly assigned to one of the four 
treatment groups: 276 to the placebo–placebo 
group, 277 to the prednisolone–placebo group, 
276 to the pentoxifylline–placebo group, and 274 
to the prednisolone–pentoxifylline group (see 
Fig. S1 in the Supplementary Appendix, available 
at NEJM.org). All the patients were followed for 
12 months or until the time of their death, with 
the exception of patients enrolled at the end of 
the trial. Owing to limitations on funding, the 
trial was stopped after all enrolled patients had 
completed at least 28 days of follow-up. At the 
time the trial was stopped, 33 patients who un-
derwent randomization during the last 90 days of 
the trial could not be included in the 90-day or 
12-month analyses. In addition, there were 159 
patients who underwent randomization within 
90 days to 12 months before the end of trial who 
could not be included in 12-month analyses. The 
four groups were well matched with regard to their 
baseline characteristics, including laboratory val-
ues (Table 1). At 28 days, 16% of the patients had 
died, 1% had been lost to follow-up, and 2% had 
withdrawn from the study. At 90 days, 29% of the 
patients (285 of 968 patients) had died, 5% had 
been lost to follow-up, 3% had withdrawn, and 4% 
had not completed follow-up owing to cessation 
of the study. At 1 year, 56% of the patients (421 
of 747 patients) had died or undergone liver trans-
plantation (3 patients), 8% had been lost to follow-
up, 4% had withdrawn, and 20% had not com-
pleted follow-up owing to cessation of the study.
End Points
At 28 days, 45 of 269 patients (17%) in the pla-
cebo–placebo group had died, 38 of 266 patients 
(14%) in the prednisolone–placebo group had died, 
50 of 258 patients (19%) in the pentoxifylline–
placebo group had died, and 35 of 260 patients 
(13%) in the prednisolone–pentoxifylline group 
had died. There was no significant treatment in-
teraction between prednisolone and pentoxifylline 
(P = 0.41). In the prespecified analysis of the pri-
mary outcome (a logistic-regression analysis that 
was adjusted for the risk category [high or inter-
mediate] used in the randomization and for the 
factorial design), the odds ratio for 28-day mor-
tality among patients who received pentoxifylline 
(those in the pentoxifylline–placebo group or those 
in the prednisolone–pentoxifylline group), as com-
pared with patients who did not receive pentoxi-
fylline was 1.07 (95% confidence interval [CI], 
0.77 to 1.49; P = 0.69), and the odds ratio among 
patients who received prednisolone (those in the 
prednisolone–placebo group or those in the pred-
nisolone–pentoxifylline group), as compared with 
patients who did not receive prednisolone, was 
0.72 (95% CI, 0.52 to 1.01; P = 0.06) (Table 2). 
Neither prednisolone nor pentoxifylline was found 
to influence mortality or the need for liver trans-
plantation at 90 days or 1 year (Table 2). Kaplan–
Meier curves for survival in each treatment group 
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Characteristic
Placebo– 
Placebo 
(N = 272)
Prednisolone– 
Placebo 
(N = 274)
Pentoxifylline– 
Placebo 
(N = 273)
Prednisolone– 
Pentoxifylline 
(N = 273)
Total 
(N = 1092)
Age — yr 48.8±10.3 49.3±10.6 47.9±10.2 48.6±9.8 48.7±10.2
Male sex — no. (%) 162 (60) 177 (65) 164 (60) 182 (67) 685 (63)
Alcohol consumption — g/day
Women 153.7±98.5 141.7±75.4 145.7±93.1 157.0±143.8 149.5±104.3
Men 195.4±126.5 209.9±117.7 192.4±129.8 201.7±127.3 200.1±125.2
Time from admission to initiation 
 of treatment — days
6.1±3.8 6.5±3.9 6.7±4.2 6.5±4.4 6.4±4.1
Encephalopathy — no. (%)†
None 191 (70) 205 (75) 211 (77) 190 (70) 797 (73)
Grade 1 46 (17) 38 (14) 33 (12) 48 (18) 165 (15)
Grade 2 19 (7) 19 (7) 16 (6) 12 (4) 66 (6)
Grade 3 5 (2) 1 (<0.5) 5 (2) 7 (3) 18 (2)
Grade 4 0 0 0 0 0
Sepsis on admission —  
no. (%)
31 (11) 27 (10) 23 (8) 29 (11) 110 (10)
Renal failure on admission —  
no. (%)‡
1 (<0.5) 0 1 (<0.5) 0 2 (<0.5)
Gastrointestinal bleeding 
on admission — no. (%)
16 (6) 21 (8) 15 (5) 15 (5) 67 (6)
Laboratory results
Bilirubin — mg/dl 17.9±9.2 17.4±9.1 17.1±8.5 17.9±9.5 17.6±9.1
Albumin — g/liter 25.6±6.3 25.2±6.2 25.1±5.4 25.3±6.0 25.3±6.0
Aspartate aminotransferase —  
U/liter
143.7±69.5 133.6±64.8 134.3±73.2 143.4±77.2 138.6±71.3
Alkaline phosphatase —  
U/liter
184.7±86.4 207.7±113.1 182.4±85.1 196.1±98.5 192.7±96.8
Creatinine — mg/dl 0.83±0.43 0.90±0.52 0.89±0.55 0.92±0.58 0.88±0.53
White-cell count — per mm3 10,100±5600 10,600±8100 9900±5400 9800±4900 10,100±6100
Neutrophils — per mm3 7600±5200 7700±5200 7400±4900 7300±4500 7500±5000
Prothrombin time — sec 21.1±5.3 20.8±5.3 22.1±6.8 21.1±5.2 21.3±5.7
Prognostic scores
Discriminant function§ 61.9±25.7 60.7±25.3 65.6±31.6 62.4±25.6 62.6±27.2
MELD¶ 20.7±5.5 21.2±6.2 21.4±6.3 21.5± 6.8 21.2±6.2
GAHS‖ 8.3±1.2 8.4±1.3 8.4±1.3 8.4±1.4 8.4±1.3
*  Plus–minus values are means ±SD. To convert the values for bilirubin to micromoles per liter, multiply by 17.1. To convert the values for 
creatinine to micromoles per liter, multiply by 88.4.
†  In patients with encephalopathy, grade 1 indicates mild confusion and impaired attention; grade 2 lethargy, personality change, and inap-
propriate behavior; grade 3 comatose behavior with responsiveness to verbal or noxious stimuli; and grade 4 coma without responsiveness 
to verbal or noxious stimuli.
‡  Renal failure was defined as a serum creatinine level greater than 5.7 mg per deciliter or the requirement for renal-support therapy.
§  Discriminant function is calculated as 4.6 × (patient’s prothrombin time in seconds − matched control’s prothrombin time in seconds) + pa-
tient’s serum bilirubin level in milligrams per deciliter; a value of 32 or higher indicates severe alcoholic hepatitis that carries an adverse 
prognosis, with mortality of 20 to 30% within 1 month after presentation and 30 to 40% within 6 months after presentation.
¶  In the Model for End-Stage Liver Disease (MELD), scores range from 6 to 40, with higher scores indicating worse prognosis.
‖  The Glasgow alcoholic hepatitis score (GAHS) ranges from 5 to 12, with higher scores indicating worse prognosis.
Table 1. Baseline Characteristics of the Patients.*
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and for survival with prednisolone versus no pred-
nisolone and with pentoxifylline versus no pent-
oxifylline are provided in Figure 1.
The baseline variables that influenced 28-day 
mortality in univariate analyses included age, en-
cephalopathy, white-cell count, prothrombin ratio, 
and serum levels of bilirubin, creatinine, and urea 
(Table 3). In multivariate analyses, age, encepha-
lopathy, white-cell count, prothrombin ratio, and 
serum levels of bilirubin, creatinine, and urea re-
mained significant. In a secondary analysis, in 
which a multivariate logistic-regression model was 
used that adjusted for these prognostic variables, 
we found that the odds ratio for 28-day mortal-
ity among the patients who received predniso-
lone, as compared with those who did not, was 
0.61 (95% CI, 0.41 to 0.91; P = 0.02) (Table 3). 
However, the effect of prednisolone on mortality 
at 90 days (odds ratio, 1.00; 95% CI, 0.73 to 1.36; 
P = 0.98) and at 1 year (odds ratio, 1.01; 95% CI, 
0.74 to 1.39; P = 0.94) was nonsignificant.
Adverse Events Including Death
Serious adverse events were reported in 42% of 
the patients, with an equal distribution in each of 
the treatment groups, and 20% of all serious ad-
verse events resulted in death. Infection occurred 
in 71 of the 547 patients (13%) who received pred-
nisolone as compared with 38 of the 545 patients 
(7%) who did not receive prednisolone (P = 0.002). 
Acute kidney injury occurred in 9 of the 546 pa-
tients (2%) who received pentoxifylline as com-
pared with 14 of the 546 patients (3%) who did not 
receive pentoxifylline (Table 4, and Table S2 in 
the Supplementary Appendix).
There were 418 deaths during the trial; 168 
(40%) of these occurred before day 29, 28% oc-
curred between day 28 and day 90, and 32% 
occurred between day 91 and 1 year. Investiga-
tors attributed 95% of the deaths to liver-related 
causes. Among these causes, infection account-
ed for 24% of the deaths, with similar numbers 
reported for the groups receiving prednisolone 
and those not receiving prednisolone. The occur-
rence of gastrointestinal bleeding, sepsis, or renal 
failure before randomization did not affect mor-
tality during the trial.
Discussion
Controversy over the use of glucocorticoids in se-
vere alcoholic hepatitis has persisted for many T
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years despite the results of meta-analyses of se-
lected trials.5,9 In our study, the reduction in 28-day 
mortality observed among patients treated with 
prednisolone did not reach the conventional 
threshold of statistical significance, and no sig-
nificant differences were observed in 90-day or 
12-month outcomes. However, in a secondary 
analysis that included adjustments for baseline 
determinants of prognosis, a significant advantage 
with respect to 28-day mortality was seen with 
prednisolone. The survival differences may have 
been a chance finding or may represent a benefit 
of prednisolone for short-term mortality that did 
not translate to longer-term benefit.
Although we used the same threshold of dis-
ease severity that has been used in most other tri-
als of alcoholic hepatitis (a score of 32 or higher 
for discriminant function), the 28-day mortality 
overall in STOPAH was appreciably lower than 
the 28-day mortality in the trials included in the 
meta-analysis by Mathurin et al.9 However, many 
of the studies included in the meta-analysis were 
performed more than 30 years ago, and the mor-
tality reported in two more recently published tri-
als was similar to that reported here.13,15,20 There 
was a lower incidence of infection and acute kidney 
injury in STOPAH than in some previous trials, 
a factor that may have contributed to the lower 
mortality.21 A comparison of the baseline char-
acteristics of the patients in our study with those 
of patients in other trials conducted in the past 
4 years shows that in our trial, the mean age was 
slightly younger and the rate of encephalopathy 
lower; both characteristics have been consistently 
shown to influence mortality.15,20 However, the 
bilirubin, creatinine, and albumin levels observed 
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Figure 1. Kaplan–Meier Curves Showing Overall  
Survival According to Study Group.
Kaplan–Meier survival curves show a nonsignificant 
survival advantage during the first 28 days among pa-
tients who received prednisolone as compared with 
those who did not receive prednisolone (odds ratio, 
0.72; 95% confidence interval [CI], 0.52 to 1.01; 
P = 0.06) (Panel A). No significant survival advantage 
was seen for patients who received pentoxifylline as 
compared with those who did not receive pentoxifyl-
line (odds ratio, 1.07; 95% CI, 0.77 to 1.49; P = 0.69) 
(Panel B). Survival curves for all four study groups up 
to 1 year are also shown (Panel C).
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in patients in STOPAH were similar to those seen 
in patients in other studies.
The use of liver biopsy to provide histologic 
confirmation of alcoholic steatohepatitis remains 
controversial.4,18,19 Although many investigators 
have used histologic confirmation as an entry 
criterion, it is rarely applied in clinical practice 
apart from those cases in which the diagnosis is 
uncertain.19 Although it is possible that the diag-
nosis of alcoholic hepatitis was incorrect in a 
small number of the patients in our study, when 
strict clinical criteria are used, it is possible to 
diagnose the condition with a high degree of 
accuracy.22 Nevertheless, incorrect diagnostic la-
beling could have reduced the power of the study 
to detect a therapeutic effect.
A recognized drawback of glucocorticoid use 
in patients with alcoholic hepatitis is increased 
susceptibility to infection.21 The higher rate of in-
fection among the patients treated with predniso-
lone was therefore expected, but mortality attrib-
uted to infection was similar across the groups, 
regardless of whether prednisolone was admin-
istered. Investigators attributed deaths to infection 
in 103 of 416 cases (24.8%), but infection also 
probably played a role in deaths attributed to other 
Variable Univariate Analysis† Multivariate Analysis‡
Odds Ratio 
(95% CI) P Value
Odds Ratio 
(95% CI) P Value
Prednisolone vs. no prednisolone 0.61 (0.41–0.91) 0.02
Pentoxifylline vs. no pentoxifylline 1.10 (0.74–1.64) 0.62
Discriminant function 1.02 (1.02–1.03) <0.001
GAHS 2.17 (1.86–2.53) <0.001
MELD 1.15 (1.12–1.18) <0.001
Lille§ 1.03 (1.02–1.03) <0.001
Prothrombin ratio or INR 1.38 (1.10–1.73) 0.005 1.38 (1.13–1.69) 0.002
Age 1.05 (1.03–1.07) <0.001 1.05 (1.03–1.07) <0.001
White cells 1.06 (1.03–1.08) <0.001 1.03 (1.00–1.06) 0.04
Urea 1.14 (1.10–1.18) <0.001 1.06 (1.01–1.12) 0.01
Creatinine 3.07 (2.32–4.08) <0.001 1.56 (1.05–2.33) 0.03
Pyrexia 0.66 (0.37–1.16) 0.15
Hypotension 1.20 (0.79–1.83) 0.39
Tachycardia 1.09 (0.71–1.65) 0.70
Alcohol intake 1.00 (1.00 –1.00) 0.37
Albumin 0.99 (0.96–1.02) 0.41
Alkaline phosphate 1.00 (1.00–1.00) 0.07
Bilirubin 1.07 (1.05–1.09) <0.001 1.03 (1.01–1.06) 0.003
Hepatic encephalopathy 3.70 (2.59–5.29) <0.001 3.07 (2.05–4.60) <0.001
*  Values reported for all variables were obtained at baseline, and the value for bilirubin was also obtained on day 7 to cal-
culate the Lille score. GAHS denotes Glasgow alcoholic hepatitis score, which ranges from 5 to 12, with higher scores 
indicating worse prognosis, INR international normalized ratio, and MELD the Model for End-Stage Liver Disease, in 
which scores range from 6 to 40, with higher scores indicating worse prognosis.
†  A separate univariate model was fitted for all baseline prognostic factors.
‡  Significant variables in the univariate analysis were added to a multivariate model, and backward elimination was ap-
plied at the 5% significance level. Prognostic scores (calculated on the basis of discriminant function, MELD, GAHS 
and Lille score) were excluded from the multivariate analysis owing to multicolinearity with individual component vari-
ables.
§  The Lille score defines the risk of death according to the number of adverse prognostic factors, with higher scores indi-
cating a worse prognosis. We calculated Lille scores on the basis of patient age, albumin level, bilirubin levels (at base-
line and on day 7), the prothrombin ratio, and prothrombin time; the formula we used is shown in the protocol.
Table 3. Analysis of Factors Associated with Mortality at 28 Days.*
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causes, such as multiorgan failure. Since infec-
tion plays such an important role in the outcome 
of alcoholic hepatitis, it is worth noting that in a 
trial published in 2011, the addition of N-acetyl-
cysteine to prednisolone was associated with a 
reduced rate of infection.20
The results of this trial showed that after 28 
days, neither prednisolone nor pentoxifylline in-
fluenced mortality. Furthermore, the cumulative 
mortality at 90 days and at 1 year in this group 
of patients is alarming. Self-reported alcohol con-
sumption revealed complete abstinence in 37% of 
the patients at 1 year of follow-up. However, data 
on alcohol consumption are difficult to collect, 
and this fact is reflected in the high proportion 
of missing data. No matter what the exact figures 
are, more clearly needs to be done to prevent re-
cidivism in this group of patients.
In summary, in the STOPAH trial, pentoxifyl-
line did not improve outcomes in patients with 
alcoholic hepatitis. The findings suggest that the 
administration of 40 mg of prednisolone daily for 
1 month may have a beneficial effect on short-
term mortality but not on the medium-term or 
long-term outcome of alcoholic hepatitis.
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Appendix
From Imperial College (M.R.T., N.V.), King’s College Hospital (J.O.), and the Royal Free Hospital (D.P.), London, Royal Liverpool 
Hospital (P. Richardson) and Aintree Hospital (S.H.), Liverpool, Addenbrookes Hospital, Cambridge (M.A.), Derby Royal Hospital, 
Derby (A.A.), Southampton Clinical Trials Unit, University of Southampton (M.B., N.D., J.M., I.R., P. Roderick, L.S.), and University 
Hospital Southampton NHS Foundation Trust (M.W.), Southampton, Faculty of Medical Sciences, Newcastle University (C.P.D.), and 
Event
Placebo– 
Placebo 
(N = 272)
Prednisolone– 
Placebo 
(N = 274)
Pentoxifylline– 
Placebo 
(N = 273)
Prednisolone– 
Pentoxifylline 
(N = 273)
Total 
(N=1092)
number of patients (percent)
Serious adverse event
Any 106 (39) 128 (47) 111 (41) 116 (42) 461 (42)
Any that led to death 53 (19) 64 (23) 58 (21) 45 (16) 220 (20)
Serious adverse event occurring in ≥5% of patients
Gastrointestinal disorder 25 (9) 40 (15) 41 (15) 40 (15) 146 (13)
Upper gastrointestinal hemorrhage 5 (2) 12 (4) 9 (3) 13 (5) 39 (4)
Ascites 6 (2) 8 (3) 11 (4) 13 (5) 38 (3)
Hepatobiliary disorder
Any 27 (10) 27 (10) 24 (9) 21 (8) 99 (9)
Hepatic failure 26 (10) 27 (10) 23 (8) 21 (8) 97 (9)
Infection or infestation†
Any 22 (8) 42 (15) 16 (6) 29 (11) 109 (10)
Lung infection‡ 11 (4) 19 (7) 6 (2) 18 (7) 54 (5)
Renal or urinary disorder 10 (4) 10 (4) 13 (5) 8 (3) 41 (4)
*  Adverse events were categorized according to the Common Toxicity Criteria for Adverse Events.
†  P = 0.002 for the comparison of serious adverse events of infection or infestation, which occurred in 71 of 547 (13%) of the patients who re-
ceived prednisolone versus 38 of 545 (7%) of the patients who did not receive prednisolone.
‡  P = 0.007 for the comparison of lung infections, which occurred in 37 of 547 (7%) of the patients who received prednisolone versus 17 of 
545 (3%) of the patients who did not receive prednisolone.
Table 4. Serious Adverse Events.*
The New England Journal of Medicine 
Downloaded from nejm.org at IMPERIAL COLLEGE LONDON on August 24, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 372;17 nejm.org April 23, 20151628
Prednisolone or Pentoxifylline for Alcoholic Hepatitis
Newcastle upon Tyne Hospitals NHS Foundation Trust (S.M.), Newcastle upon Tyne, Sheffield Teaching Hospitals Foundation Trust, 
Sheffield (D.G.), Edinburgh Royal Infirmary, Edinburgh (A. MacGilchrist), Leicester Royal Infirmary, Leicester (A.G.), Bristol Royal 
Infirmary, Bristol (A. McCune), Nottingham University Hospitals NHS Trust and National Institute for Health Research Biomedical 
Research Unit, Queens Medical Centre, Nottingham (S.R.), and the Glasgow Royal Infirmary, Glasgow (E.H.F.) — all in the United 
Kingdom.
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